hrp0095p1-295 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Continuous Glucose Monitoring for hypoglycaemia: the unheard patient voice

N Ahmad Sumera , Worth Chris , Auckburally Sameera , Soloman-Estebanez Maria , O'Shea Elaine , Worthington Sarah , Banerjee Indraneel

Background & Aims: Hypoglycaemia is a constant threat for all patients with congenital hyperinsulinism (CHI) and, left untreated, can lead to neurological damage and impaired development. To improve glycaemic monitoring, self-monitoring-blood-glucose (SMBG) is increasingly being replaced by Continuous Glucose Monitoring (CGM) with potential to identify illness patterns and treatment responses although with unproven benefit for patients and families. Explor...

hrp0097rfc10.2 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) & Multisystem endocrine disorders | ESPE2023

Utility of Continuous Glucose Monitoring (CGM) during pancreatic surgery in patients with Congenital Hyperinsulinism

Worthington Sarah , Worth Chris , O'Shea Elaine , Ahmad Sumera , Bowler Matthew , Beauve Benoit , Salomon-Estebanez Maria , Banerjee Indraneel

Introduction: Congenital Hyperinsulinism (CHI) is a rare disease of hypoglycaemia due to excess insulin production. Patients with both focal and diffuse forms of CHI may have severe hypoglycaemia not responsive to medical therapies. Such patients require lesionectomy or subtotal pancreatectomy with a corresponding necessity for enhanced glycaemic monitoring during the peri-operative period. Subcutaneous Continuous Glucose Monitoring (CGM) provides real-time hi...

hrp0097p1-279 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

A Year-Long, National Trial of Prospective CGM Use in Families with Hyperinsulinism

Worth Chris , Worthington Sarah , Auckburally Sameera , Ahmad Sumera , O'Shea Elaine , Ferrera-Cook Chris , F Betz Stephen , Salomon-Estebanez Maria , Banerjee Indraneel

Introduction: Congenital hyperinsulinism (CHI) is the commonest cause of severe hypoglycaemia in early childhood but glycaemic characterisation remains scarce. Continuous glucose monitoring (CGM) offers a deep understanding of glycaemic control to understand disease burden, individualise patient care and inform therapeutic trials in CHI. Preliminary studies suggest inadequate accuracy and no efficacy of standalone CGM to reduce hypoglycaemia. Provision is hist...